Rare Disease Deal Benchmarks
Rare disease assets benefit from 15-25% probability of success vs 7-12% overall, orphan drug exclusivity, and premium pricing power. Benchmark gene therapy, SMA, Duchenne, hemophilia, and orphan drug deal structures. Benchmarks derived from 403 verified transactions.
403
Total Deals
$207M
Avg Upfront
7
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
186
license
86
acquisition
89
collaboration
35
option
5
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Alesta Therapeutics → BioMarin Pharmaceutical ALE1 | acquisition | $275M | $490M | Aug 2026 |
AB2 Bio → Nippon Shinyaku Tadekinig alfa | option | $30M | $630M | Jul 2026 |
Dimerix Limited → Mission Therapeutics Limited DMX-652 | acquisition | $5M | $292M | Jul 2026 |
Sangamo Therapeutics, Inc. → Astellas Pharma Inc. isaralgagene civaparvovec (ST-920) | acquisition | $25M | $50M | Jun 2026 |
Haisco Pharmaceutical Group → Nuvectis Pharma, Inc. NXP100 (HSK39297/Ciprocopan Succinate) and NXP200 (HSK42360) | license | $20M | $1.4B | Jun 2026 |
Ionis Pharmaceuticals, Inc. → Recordati ZANVASTRO (zilganersen) | license | $30M | — | Jun 2026 |
Inceptive Nucleics → Alnylam Pharmaceuticals AI-assisted siRNA design platform collaboration | collaboration | $30M | $2.0B | Jun 2026 |
Oscotec → Agios Pharmaceuticals cevidoplenib | license | $25M | $165M | Jun 2026 |
Edgewise Therapeutics, Inc. → Servier Pharmaceuticals LLC / Les Laboratoires Servier sevasemten | acquisition | $1.6B | $2.6B | Jun 2026 |
Hanmi Pharm → Eli Lilly and Company sonefpeglutide | license | $75M | $1.3B | May 2026 |
Benchmark Your Rare Disease Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 403 verified rare disease transactions.
Rare Disease Deal Benchmarking FAQ
Why do rare disease deals command premium valuations?
Rare disease assets benefit from higher probability of success (15-25% vs 7-12% for all indications), 7 years of orphan drug market exclusivity, expedited regulatory pathways (Breakthrough Therapy, Accelerated Approval), and premium pricing ($200K-$3M+ per patient per year). These structural advantages drive higher upfronts and total deal values relative to patient population size.
How are gene therapy deal structures evolving in 2026?
Gene therapy deals are shifting toward outcomes-based structures as payers demand evidence of durability. Upfronts remain substantial ($50M-$300M for clinical-stage assets), but milestones increasingly tie to long-term efficacy data (2-5 year follow-up). Royalties on gene therapies are typically lower (8-15%) but are applied to products priced at $1M-$3M+ per treatment.
What deal terms are typical for rare disease licensing agreements?
Rare disease licensing deals typically feature upfronts of $30M-$200M for clinical-stage assets, total deal values of $500M-$2B+, and royalties of 10-20%. Geographic splits are common, with licensors retaining the US/EU and licensing ex-US rights. Development milestones are often weighted toward regulatory rather than commercial events.